The recent progress of drug delivery technologies has been contributing to the increase in the number and variety of modified-release drug products approved in Japan. Those products have many clinical benefits for pharmacotherapy, such as reducing dosing frequency, maintaining therapeutic effect, decreasing side effect/toxicity, and increasing pharmacological selectivity/specificity. For a successful drug design and clinical development of this type of drug products, adequate planning and step-by-step evaluation is very important.